¥2,555.50
0.93%
Tokyo, Nov 18, 02:39 pm JST. Closed.
ISIN
JP3256000005
Symbol
4151
Index

Kyowa Kirin Stock price

¥2,552.50
+224.50 9.64% 1M
+247.00 10.71% 6M
+25.50 1.01% YTD
+53.50 2.14% 1Y
+111.50 4.57% 3Y
-842.50 24.82% 5Y
+888.50 53.40% 10Y
+1,663.50 187.12% 20Y
Tokyo, Closing price Wed, Nov 18 2026
-27.00 1.05%
ISIN
JP3256000005
Symbol
4151
Index
Industry

Is Kyowa Kirin a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
¥1.4t
Enterprise Value
¥1.1t
Net debt
positive
Cash
¥241.9b
Shares outstanding
523.6m
Valuation
P/E
15.7
P/S | estimate
2.6 | 2.5
EV/Sales | estimate
2.1 | 2.1
EV/FCF | ex SBC
31.0 | -
P/B
1.5
Dividends
DPS
¥70.00
Yield 1Y | 5Y
2.7% | 2.2%
Growth 1Y | 5Y
12.9% | 8.8%
Payout 1Y | 3Y
48.4% | 44.9%
Increased
10 Years
Financials
Revenue | estimate
¥532.3b | ¥535.2b
EBITDA
¥105.4b
EBIT
¥96.5b
Net Income
¥86.1b
Free Cash Flow | ex SBC
¥36.0b | -
Growth
Revenue | estimate
10.4% | 7.7%
EBITDA
16.9%
EBIT
47.5%
Net Income
135.5%
Free Cash Flow
218.5%
Margin
Gross
74.7%
EBITDA
19.8%
EBIT
18.1%
Net
16.2%
Free Cash Flow | ex SBC
6.8% | -
Financial Health
Equity Ratio
80.6%
Return on Equity
7.5%
ROCE
10.3%
ROIC
11.5%
Debt/Equity
0.0
More
EPS
¥164.5
FCF per Share
¥68.8
Short interest
-
Employees
5k
Rev per Employee
¥96.3m

Kyowa Kirin Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Kyowa Kirin forecast:

1x Buy
6%
7x Hold
39%
10x Sell
56%

Analyst Opinions

18 Analysts have issued a Kyowa Kirin forecast:

Buy
6%
Hold
39%
Sell
56%

Financial data from Kyowa Kirin

Sep '26
+/-
%
532,322 532,322
10% 10%
100%
- Direct Costs 134,456 134,456
5% 5%
25%
397,866 397,866
13% 13%
75%
- Selling and Administrative Expenses 167,600 167,600
1% 1%
31%
- Research and Development Expense 92,046 92,046
13% 13%
17%
105,365 105,365
17% 17%
20%
- Depreciation and Amortization 8,821 8,821
64% 64%
2%
EBIT (Operating Income) EBIT 96,544 96,544
48% 48%
18%
Net Profit 86,114 86,114
135% 135%
16%

In millions JPY.

Don't miss a Thing! We will send you all news about Kyowa Kirin directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kyowa Kirin Stock News

Neutral
Business Wire
●
about 2 months ago
GALASHIELS & MARLOW, U.K.--(BUSINESS WIRE)--Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribution agreement with Knight Therapeutics (“Knight”) (TSX: GUD) for the distribution of mogamulizumab in select countries in Latin America. Under the terms of the agreement, Knight will be responsible...
Positive
WSJ
●
3 months ago
The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said
Neutral
GlobeNewsWire
●
5 months ago
New online resource brings together practical information, community perspectives, and expert guidance tailored to people with XLH across ages and life stages New online resource brings together practical information, community perspectives, and expert guidance tailored to people with XLH across ages and life stages

Company Profile

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It operates through the Pharmaceuticals and Bio-Chemicals segments. The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. The Bio-Chemicals segment produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Dr. Miyamoto
Employees 5,161
Founded 1949
Website www.kyowakirin.co.jp

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today